RTTNews BiotechCodex · 实盘可交易 · 做多市场:美股▼ 亏 -2.68% · 已结算把握 5/10
北京时间·🕒 发布 12:44:18时区推断·⟳ 抓取 12:45:19·⚡ 决策 08-07 21:28:58 +8h43m·81.2 天前
Replimune的TUDRIQEV联合nivolumab获FDA加速批准用于晚期黑色素瘤
FDA最终加速批准使Replimune从临床阶段进入商业阶段，TUDRIQEV成为公司首个可销售产品，解除7月顾问委员会后仍悬而未决的监管二元风险。
📄 原文RTTNews Biotech↗ 原文
Replimune Wins FDA Accelerated Nod For TUDRIQEVTM In Advanced Melanoma
Replimune Group, Inc. (REPL) announced that the U.S. FDA has granted accelerated approval for TUDRIQEVTM, in combinatio…
▼ 亏 -2.68%入场 08-07 盘前首笔 @12.97 → 离场 08-10 常规开盘 @12.64
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑最终获批去风险，低开平开才参与
怎么买 限价买入 不高于昨收 +4%、仅下一个交易日，不成交作废
怎么卖 止盈 +6%(半仓)/+14%(清仓) · 止损 -10% · 时间止损 3日
不做 Iovance Biotherapeutics（IOVA.US）
TUDRIQEV获批对Amtagvi构成竞争风险，但IOVA同日自身大涨且商业替代率尚未量化，不满足强空入场条件；仅保留风险信号用于禁止新多/减仓评估。
不做 Bristol Myers Squibb（BMY.US）
Opdivo作为联合用药方的增量未披露，且相对BMY超大体量太小，缺乏短线市值级重定价edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 REPL.US Replimune Group
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做多 REPL.US Replimune Group
| 收益状态 | -2.68% 已平仓 |
|---|---|
| 进场成交 | 2026-08-07 · 盘前首笔 · 08-07 16:01 北京 · @12.9694 |
| 离场成交 | 2026-08-10 · 常规开盘 · @12.64 |
| 毛收益 | -2.54% |
| 成本 | +0.14% |
| 净收益 | -2.68% |
| 计入收益 | -2.68% |
| 建仓日 | 2026-08-07 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-28 01:19
研究档案
消息传播链
- Replimune盘后公告FDA加速批准TUDRIQEV联合nivolumab用于anti-PD-1治疗后进展的不可切除晚期皮肤黑色素瘤成人患者。
- 公司提交8-K并召开TUDRIQEV获批投资者电话会，披露标签、IGNYTE数据、确证试验和商业化准备。
- RTTNews在美股盘前转述获批事件和ORR 24.2%、中位DOR 14.1个月等核心数据。
- 2026-08-07 09:01 ET市场反应stock_quote非一手盘前报价显示REPL约12.75美元，较8月6日收盘价12.86美元小幅回落，说明正式获批后的追加买盘并不失控。市场反应:REPL.US盘前约低于前收1%。
关键理由
- FDA最终加速批准使Replimune从临床阶段进入商业阶段，TUDRIQEV成为公司首个可销售产品，解除7月顾问委员会后仍悬而未决的监管二元风险。
- 量级上，REPL此前几乎没有产品收入；卖方在PDUFA前估算RP1美国峰值销售约6亿-6.5亿美元，本次获批把该商业化期权从概率资产转成真实上市产品。
- 先例显示小盘biotech首个肿瘤/罕见病产品获批常有首日上行动量，但REPL在7月31日AdCom后单日+107%、近5日+138%，因此只在开盘涨幅受控时小仓参与。
主要风险
- TUDRIQEV为加速批准，持续上市依赖IGNYTE-3等确证试验验证临床获益，若试验或标签执行不及预期会快速回吐。
- 股价已经围绕AdCom和PDUFA显著抢跑，若开盘超过前收4%或高开低走，剩余edge不足。
- 先例样本虽方向偏正，但缺少统一event_study逐日超额收益面板，涨幅口径只能保守使用。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-08-06 · 影响 weakens
反证显示TUDRIQEV仍为加速批准且公司商业化经验有限，确证试验、制造和报销是主要风险；不否定获批利好，但压低仓位。
检索:Replimune recent bearish risks cash runway FDA CRL dilution TUDRIQEV commercialization 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-07-31 · 影响 weakens
内部库命中7月30日AdCom支持和8月2日PDUFA预期，说明本次正式获批不是完全低扩散突发。
检索:Replimune TUDRIQEV RP1 melanoma FDA approval revenue market size nivolumab 原文 ↗ - 做空前查反向 · 来源 kb_search · 日期 2026-05-13 · 影响 weakens
IOVA仍有Amtagvi销售恢复、产能维护结束和其他适应症机会等正面叙事，因此REPL竞争者获批更适合作为风险过滤而非直接开空。
检索:Iovance Amtagvi recent bullish risks sales growth guidance capacity 2026 原文 ↗ - 做空前查反向 · 来源 stock_quote · 日期 2026-08-06 · 影响 weakens
IOVA前一交易日大涨约43%、量比约4.5，显示有自身正向催化和拥挤波动，直接追空胜率不足。
检索:IOVA.US detail=full
先例如何影响了这次决策
对本次决策的影响:先例没有推翻做多方向，但把仓位维持small、入场从10%追涨上限收紧到前收+4%，并把持有期从5日压到3日。
方向:高相似先例整体偏正，IOVA、IBRX、DAWN显示首个肿瘤/免疫产品获批通常能带来首日买盘，但不是无条件追高。
涨幅量级:高相似样本公开报道的首日反应约+11%至+37%，但REPL已因AdCom提前+107%，因此本次只取残余6%-14%作为止盈区间。
形态:IBRX和SRPT提示获批后若预期已高或标签/商业化限制被重新审视，容易高开收窄甚至见光死；REPL的AdCom抢跑使这个风险偏高。
历史先例(按相似度)
- 相似度 9/10 IOVA.US 2024-02-16 Iovance的Amtagvi获FDA加速批准用于anti-PD-1后晚期黑色素瘤。 原文 ↗
事件后 +1日 -7.3% · +2日 +21.9% · +3日 +59.8% · +4日 +61.5% · +5日 +59.8%
⚠盘中首发但只有日线，混入首发前走势·相位不对齐(open!=target_pre) — 该行涨幅别用来定止盈止损
相似度依据:同为美股小盘肿瘤biotech、晚期黑色素瘤、anti-PD-1后治疗、加速批准并从临床期转商业期。
经验:首个商业化产品获批会触发显著重估，但节假日后首个交易日追高仍要防融资稀释。 - 相似度 8/10 IBRX.US 2024-04-22 ImmunityBio的ANKTIVA获FDA批准用于BCG无反应NMIBC。 原文 ↗
事件后 +1日 +11.1% · +2日 -2.4% · +3日 +3.4% · +4日 +48.8% · +5日 +82.0%
⚠相位不对齐(post!=target_pre) — 该行涨幅别用来定止盈止损
相似度依据:同为此前遭拒后重新获批的美股免疫肿瘤公司，且获批后从研发叙事进入商业化。
经验:经历CRL后获批可解除二元监管折价，但次日高开幅度大时收盘收益会明显低于盘前涨幅。 - 相似度 7/10 DAWN.US 2024-04-23 Day One的OJEMDA获FDA加速批准用于BRAF改变复发/难治儿童低级别胶质瘤。 原文 ↗
Bloomberg报道DAWN盘中最多上涨约13%。
相似度依据:同为美股小盘肿瘤公司首个产品加速批准并获得PRV，但适应症和商业规模不同。
经验:若标签范围优于担忧，获批当天仍可上涨；但这种案例更适合校准小仓追随而非重仓。 - 相似度 6/10 SWTX.US 2023-11-27 SpringWorks的OGSIVEO获FDA批准用于进展性硬纤维瘤。 原文 ↗
公开报道显示SWTX盘后约+16%、次日收涨约18.7%。
相似度依据:同为美股biotech首个产品获批且成为商业化公司，但不是加速批准肿瘤免疫、适应症更罕见。
经验:首个且唯一疗法获批可带来10%-20%级别首日反应，尤其在全年未明显抢跑时。 - 相似度 5/10 MDGL.US 2024-03-14 Madrigal的Rezdiffra获FDA加速批准用于NASH/MASH。 原文 ↗
事件后 +1日 +11.0% · +2日 +16.3% · +3日 +9.1% · +4日 +6.3% · +5日 +4.8%
相似度依据:同为加速批准和首个商业大适应症，但市场空间、公司市值和非肿瘤机制均不同。
经验:若标签比市场担忧更干净，即使PDUFA可预期，正式获批仍能推动15%左右首日重估。 - 相似度 5/10 KRYS.US 2023-05-19 Krystal的VYJUVEK获FDA批准用于营养不良性大疱性表皮松解症。 原文 ↗
事件后 +1日 +9.8% · +2日 +34.4% · +3日 +36.2% · +4日 +35.5% · +5日 +34.2%
⚠盘中首发但只有日线，混入首发前走势 — 该行涨幅别用来定止盈止损
相似度依据:同为首个产品/基因疗法获批，但KRYS商业确定性更高且获批为盘中事件。
经验:盘中获批若不是完全意外，首日反应可只有高个位数，但后续商业化兑现才决定趋势。 - 相似度 4/10 SRPT.US 2023-06-22 Sarepta的ELEVIDYS获FDA加速批准用于4-5岁DMD患者。 原文 ↗
事件后 +1日 -7.9% · +2日 -12.6% · +3日 -14.1% · +4日 -9.7% · +5日 -9.4%
相似度依据:同为加速批准、确证试验依赖和高预期监管事件，但市值更大且标签限制争议更强。
经验:若获批标签窄于市场预期，正式批准也可能成为兑现点，不能只看批准二字追高。
工具调用 · 历史记录,结果未知(5 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- kb_fetch_document · 结果未知
- validate_order · 结果未知
原文全文
展开原文 · 2,622 字
Replimune Group, Inc. (REPL) announced that the U.S. FDA has granted accelerated approval for TUDRIQEVTM, in combination with Nivolumab (Bristol Myers Squibb), for adults with unresectable advanced cutaneous melanoma who have progressed following anti-PD-1 antibody-based therapy.
Advanced melanoma patients often face limited treatment options, with more than half experiencing disease progression. Prognosis after progression is poor, with median overall survival typically less than one year.
TUDRIQEVTM (vusolimogene oderparepvec-wtpg) is an oncolytic immunotherapy designed to selectively replicate within tumors and stimulate an anti-tumor immune response. It is administered by intratumorl injection into superficial and deep and/or visceral lesions. For deep/visceral tumors, administration is guided by imaging technology. The recommended dose is based on tumor size.
The FDA's decision was supported by data from the IGNYTE trial which enrolled 140 patients. In the efficacy-evaluable group, TUDRIQEV plus nivolumab achieved an objective response rate of 24.2% and a median duration of response of 14.1 months. The regimen was generally well tolerated, with mostly mild-to-moderate adverse events.
"This is a transformative moment for Replimune, marking years of pioneering research to bring TUDRIQEV to patients desperately in need of new treatment options for advanced melanoma," said Sushil Patel, Ph.D., CEO of Replimune. Michael K. Wong, MD, PhD, primary investigator of the IGNYTE study, added that the therapy offers a potent oncolytic immunotherapy option across a broad patient population, with a favorable risk-benefit profile.
The approval was granted under the FDA's accelerated pathway, based on objective response rate and duration of response. Continued approval may depend on confirmatory trials to verify clinical benefit.
REPL has traded between $1.50 and $13.90 over the past year. The stock closed Thursday's trading at $12.86, up 8.71%. During the overnight trading session, the stock is at $12.73, down 1.01%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 01, 2026 02:10 ET Major central banks, led by the U.S. Federal Reserve, and preliminary estimates of second quarter economic growth dominated the economics news flow this week. In the U.S., the Federal Reserve announced its latest policy decision and early estimates of second quarter growth and monthly inflation data were also released. In Europe, the interest rate decision from the Bank of England was in focus. Similarly, the Bank of Japan was in the limelight in Asia for its policy announcement.
Advanced melanoma patients often face limited treatment options, with more than half experiencing disease progression. Prognosis after progression is poor, with median overall survival typically less than one year.
TUDRIQEVTM (vusolimogene oderparepvec-wtpg) is an oncolytic immunotherapy designed to selectively replicate within tumors and stimulate an anti-tumor immune response. It is administered by intratumorl injection into superficial and deep and/or visceral lesions. For deep/visceral tumors, administration is guided by imaging technology. The recommended dose is based on tumor size.
The FDA's decision was supported by data from the IGNYTE trial which enrolled 140 patients. In the efficacy-evaluable group, TUDRIQEV plus nivolumab achieved an objective response rate of 24.2% and a median duration of response of 14.1 months. The regimen was generally well tolerated, with mostly mild-to-moderate adverse events.
"This is a transformative moment for Replimune, marking years of pioneering research to bring TUDRIQEV to patients desperately in need of new treatment options for advanced melanoma," said Sushil Patel, Ph.D., CEO of Replimune. Michael K. Wong, MD, PhD, primary investigator of the IGNYTE study, added that the therapy offers a potent oncolytic immunotherapy option across a broad patient population, with a favorable risk-benefit profile.
The approval was granted under the FDA's accelerated pathway, based on objective response rate and duration of response. Continued approval may depend on confirmatory trials to verify clinical benefit.
REPL has traded between $1.50 and $13.90 over the past year. The stock closed Thursday's trading at $12.86, up 8.71%. During the overnight trading session, the stock is at $12.73, down 1.01%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 01, 2026 02:10 ET Major central banks, led by the U.S. Federal Reserve, and preliminary estimates of second quarter economic growth dominated the economics news flow this week. In the U.S., the Federal Reserve announced its latest policy decision and early estimates of second quarter growth and monthly inflation data were also released. In Europe, the interest rate decision from the Bank of England was in focus. Similarly, the Bank of Japan was in the limelight in Asia for its policy announcement.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。